ROTATEQ™ Post-Marketing Surveillance in the Philippines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01357174
Recruitment Status : Terminated (Merck Sharp & Dohme Corp (MSD) received exemption from PFDA on conduct of post-marketing surveillance (PMS) study)
First Posted : May 20, 2011
Last Update Posted : October 30, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This study will collect demographic and safety information on the use of ROTATEQ™ in the Philippines.

Condition or disease
Rotavirus Infections Gastroenteritis

Study Type : Observational
Actual Enrollment : 915 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Protocol for ROTATEQ™ Post-Marketing Surveillance
Study Start Date : October 2007
Actual Primary Completion Date : September 2010
Actual Study Completion Date : September 2010

All Participants
Infants who were vaccinated with ROTATEQ™

Primary Outcome Measures :
  1. Number of participants with adverse events following administration of ROTATEQ™ [ Time Frame: Three-year period following vaccine marketing approval (August 2007 to August 2010) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Weeks to 12 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Infants in the Philippines who received ROTATEQ.™ Information will be provided by the physicians who administered the vaccine.

Inclusion Criteria:

  • Received ROTATEQ™

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01357174     History of Changes
Other Study ID Numbers: V260-046
First Posted: May 20, 2011    Key Record Dates
Last Update Posted: October 30, 2015
Last Verified: October 2015

Additional relevant MeSH terms:
Rotavirus Infections
Gastrointestinal Diseases
Digestive System Diseases
Reoviridae Infections
RNA Virus Infections
Virus Diseases